Expert Interview
Discussing Priovant Therapeutics’ Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis
Ticker(s): PRIOVANT THERAPEUTICSInstitution: University of Iowa
- Clinical Assistant Professor of Dermatology and Director of the Skin of Color Clinic
- Manages 10 patients per year with cutaneous sarcoidosis and treats a high volume of dermatology and skin cancer patients, including complex cutaneous oncology cases requiring Mohs surgery
- Specializes in dermatologic surgery and cutaneous oncology, with expertise in Mohs micrographic surgery for skin cancer; actively involved in academic research and education focused on skin cancer outcomes, dermatologic health equity, and improving care for skin of color populations
How many patients do you manage with Cutaneous Sarcoidosis?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for Brepocitinib as a potential treatment for Cutaneous Sarcoidosis?
Added By: lilly_adminHow much of a game changer would an FDA approved medication for Cutaneous Sarcoidosis be?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
